SKI3 Antibody
Description
Applications and Dilution Guidelines
The antibody is optimized for multiple experimental techniques, with specific dilution ranges cited in Table 2.
| Application | Suggested Dilution | References |
|---|---|---|
| Western Blot (WB) | 1:300–1:5000 | |
| Immunofluorescence | 1:50–1:200 | |
| ChIP-qPCR | 1–5 µg per assay |
Role of SKI3 in mRNA Degradation Pathways
SKI3 is a core subunit of the SKI complex (Ski2-Ski3-Ski8), which collaborates with the RNA exosome to degrade cytoplasmic transcripts via 3′→5′ exonucleolysis . Key findings include:
-
Ribosome Interaction: SKI3 binds directly to the ribosome’s small subunit, facilitating mRNA surveillance pathways such as Non-Stop Decay (NSD) and No-Go Decay (NGD) .
-
Ska1-Dependent Subcomplex: SKI3 associates with Ska1 to degrade ribosome-free RNA regions (e.g., long 3′UTRs, cytoplasmic lncRNAs) . Overexpression of Ska1 disrupts SKI-ribosome interactions, redirecting activity to non-translated RNAs .
Antibody Validation and Performance
The SKI3 antibody has been validated in diverse experimental systems:
-
Western Blot: Detects SKI3 in human cell lysates at dilutions up to 1:5000, with specific band patterns confirmed by knockdown/knockout controls .
-
Immunofluorescence: Localizes SKI3 to cytoplasmic puncta and ribosomal clusters, consistent with its role in mRNA surveillance .
-
ChIP-qPCR: Maps SKI3 binding to chromatin regions, though applications are less common compared to cytoplasmic studies .
Comparative Analysis of SKI3 Antibody Sources
Table 3 highlights key differences between commercial SKI3 antibodies.
| Vendor | Catalog # | Conjugation | Applications | Key Features |
|---|---|---|---|---|
| Bioss | bs-53094R | Unconjugated | WB, IF | Protein G purified; azide/ProClin300 buffer |
| Diagenode | C15410011 | Unconjugated | WB, IF, ChIP-qPCR | ChIP-grade; validated in multiple assays |
| Thermo Fisher | PA5-40078 | Unconjugated | ICC/IF | Focus on cytoplasmic localization studies |
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
Q&A
Basic Research Questions
What experimental approaches validate SKI3 antibody specificity in ribosome-associated complexes?
-
Perform co-sedimentation assays using sucrose gradient fractionation combined with Western blotting (1:100 dilution recommended). Pre-treat lysates with RNase to distinguish between mRNA-mediated associations and direct ribosome binding .
-
Validate using SKI3-TAP affinity purification followed by mass spectrometry to confirm co-purification with SKI2, SKI8, and exosome components (Rrp41, Rrp42, etc.) .
How does SKI3 antibody aid in studying cytoplasmic RNA decay pathways?
-
Use in chromatin immunoprecipitation (ChIP; 1–5 μg/ChIP) to map SKI3 binding sites on ribosome-free RNA substrates (e.g., long 3′UTRs or cytoplasmic lncRNAs) .
-
Combine with ΔSKA1 mutants to isolate SKI complexes specifically involved in ribosome-associated decay vs. ribosome-free RNA degradation .
Advanced Research Questions
How to resolve contradictory data on SKI3’s role in ribosome-associated vs. ribosome-free RNA degradation?
What methodologies distinguish SKI3’s role in viral RNA attenuation vs. canonical mRNA decay?
-
Use ski3Δ/Δ yeast strains to study Killer virus (M1) accumulation during sporulation. Monitor toxin levels via Northern blotting and viability assays .
-
Compare SKI3 antibody performance in mitotic vs. meiotic cells:
Methodological Considerations
How to optimize SKI3 antibody for co-translational decay studies?
-
Critical controls:
-
Quantitative metrics:
What orthogonal techniques complement SKI3 antibody-based findings?
Data Interpretation Frameworks
How to address background noise in SKI3 antibody-based ChIP experiments?
-
Pre-clear lysates with protein A/G beads before immunoprecipitation .
-
Use Δski3 strains as negative controls for nonspecific binding.
